Pimozide
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Pimozide: From Tourette Syndrome to Trichotillomania
One-Sentence Summary
Pimozide is a diphenylbutylpiperidine-class antipsychotic historically used as a backup treatment for Gilles de la Tourette syndrome. The TxGNN model predicts it may be effective for Trichotillomania, currently supported by 0 clinical trials and 10 publications (mostly reviews, open-label series, and case reports).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Gilles de la Tourette syndrome (per literature reference; no Taiwan/US license record in this pack) |
| Predicted New Indication | Trichotillomania |
| TxGNN Prediction Score | 99.996% |
| Evidence Level | L3 |
| US Market Status | ✗ Not Marketed (未上市) |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information cited in the evidence pack, pimozide is a diphenylbutylpiperidine-class antipsychotic and a potent dopamine D2 receptor antagonist. In the US it is FDA-approved only as a backup treatment for Gilles de la Tourette syndrome, though it has historically been used in other countries for schizophrenia.
Trichotillomania and Tourette syndrome are both considered part of the broader obsessive-compulsive/impulse-control spectrum, with overlapping phenomenology and, in some patients, comorbidity. The mechanistic hypothesis is that dopaminergic pathways participate in compulsive-impulsive behaviors (including hair-pulling), which parallels pimozide’s established role as an augmentation agent for tic disorders.
Supporting this rationale, the evidence pack includes an early open-label case series (PMID 1532960, Stein & Hollander, 1992) describing low-dose pimozide augmentation of serotonin reuptake blockers for trichotillomania, consistent with the augmentation logic used in refractory OCD-spectrum conditions. However, this is not first-line evidence — the majority of supporting literature consists of reviews and case reports rather than controlled trials, and there are currently no registered clinical trials specifically evaluating pimozide in trichotillomania.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 1532960 | 1992 | Open-label/Case series | J Clin Psychiatry | Low-dose pimozide augmentation of SRI in refractory trichotillomania |
| 36802832 | 2023 | Evidence mapping/Review | J Cutan Med Surg | Evidence mapping of RCTs for pharmacological management of primary psychodermatologic disorders |
| 15554735 | 2004 | Review | Am J Clin Dermatol | Comprehensive review of pimozide in dermatologic practice; notes off-label use for monosymptomatic hypochondriacal psychosis |
| 30446201 | 2018 | Review | Clin Dermatol | Antipsychotics in dermatology; central D2 blockade may affect cutaneous perception/behavior |
| 27320510 | 2016 | Review | Tijdschr Psychiatr | Treatment options for pediatric trichotillomania; notes limited pharmacotherapy research |
| 10497682 | 1999 | Review | Ann Acad Med Singapore | Under-diagnosed psychiatric syndromes, including trichotillomania |
| 28225970 | 2017 | Case report | An Bras Dermatol | Trichotillomania case with dermatoscopic differential diagnosis vs alopecia areata |
| 11475941 | 2001 | Review (related disorder) | CNS Drugs | Psychogenic excoriation clinical features and treatment approaches |
| 10357517 | 1999 | Case series (risperidone, non-pimozide) | J Child Adolesc Psychopharmacol | Risperidone addition in SRI-refractory trichotillomania (non-pimozide comparator) |
| 10900563 | 2000 | Case series (related disorder) | Int J Psychiatry Med | Delusional parasitosis clinical profile |
US Market Information
Pimozide is currently not marketed in this jurisdiction — no license/authorization records are available (0 NDAs on file).
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence for the trichotillomania indication is currently limited to L3-level evidence (mostly reviews, case reports, and a single small open-label series from 1992), with no completed clinical trials. Combined with the absence of TFDA/package-insert warnings and contraindications data (a Blocking data gap), the candidate is not yet ready to enter safety evaluation (S1).
To proceed, the following is needed:
- TFDA/regulatory package-insert data on warnings and contraindications (resolves Blocking gap DG001)
- Detailed mechanism of action data from DrugBank (resolves High-severity gap DG002)
- Prospective or controlled trial data specifically in trichotillomania, given current evidence is confined to decades-old open-label/case-series reports
- A formal pharmacovigilance and monitoring plan before any clinical exploration, given the drug is not currently marketed in this jurisdiction
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.